| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $2,305,990 | 9 | 30 |
Sells | $27,508,461 | 21 | 70 |
| SIEGALL CLAY B | President and CEO | 4 | $1.75M | 0 | $0 | $1.75M |
| BIENAIME JEAN JACQUES | director | 4 | $351,430 | 1 | $203,820 | $147,610 |
| Tsai Philip | Chief Technical Officer | 1 | $204,900 | 0 | $0 | $204,900 |
| Higgins Jack | Chief Scientific Officer | 0 | $0 | 2 | $538,462 | $-538,462 |
| WAGENHEIM PHILIP | director | 0 | $0 | 2 | $1.34M | $-1.34M |
| Horn Kinney | CHIEF BUSINESS OFFICER | 0 | $0 | 2 | $2.3M | $-2.3M |
| Lechleider Robert | Chief Medical Officer | 0 | $0 | 2 | $2.34M | $-2.34M |
| Rosett Max | Chief Financial Officer | 0 | $0 | 2 | $2.52M | $-2.52M |
| Barchas Isaac | director | 0 | $0 | 10 | $18.27M | $-18.27M |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including …
Over the last 12 months, insiders at Immunome, Inc. have bought $2.31M and sold $27.51M worth of Immunome, Inc. stock.
On average, over the past 5 years, insiders at Immunome, Inc. have bought $2.2M and sold $13.89M worth of stock each year.
Highest buying activity among insiders over the last 12 months: SIEGALL CLAY B (President and CEO) — $1.75M. BIENAIME JEAN JACQUES (director) — $351,430. Tsai Philip (Chief Technical Officer) — $204,900.
The last purchase of 10,500 shares for transaction amount of $204,260 was made by BIENAIME JEAN JACQUES (director) on 2026‑06‑05.
| 2026-09-11 | Sale | Higgins Jack | Chief Scientific Officer | 13,200 0.012% | $25.32 | $334,224 | -20.75% | |
| 2026-08-12 | Sale | Barchas Isaac | director | 11,048 0.0113% | $27.25 | $301,058 | -18.19% | |
| 2026-08-11 | Sale | Barchas Isaac | director | 62,291 0.0651% | $26.23 | $1.63M | -10.63% | |
| 2026-08-10 | Sale | Barchas Isaac | director | 10,125 0.0092% | $26.07 | $263,959 | -7.77% | |
| 2026-08-07 | Sale | Barchas Isaac | director | 15,248 0.0143% | $26.06 | $397,363 | -4.39% | |
| 2026-08-06 | Sale | Barchas Isaac | director | 20,840 0.0189% | $26.06 | $543,090 | -7.28% | |
| 2026-08-04 | Sale | Horn Kinney | CHIEF BUSINESS OFFICER | 90,616 0.0949% | $25.09 | $2.27M | -4.39% | |
| 2026-07-07 | Sale | Barchas Isaac | director | 16,906 0.0179% | $24.20 | $409,125 | -5.51% | |
| 2026-07-07 | Sale | Horn Kinney | CHIEF BUSINESS OFFICER | 1,092 0.0012% | $25.00 | $27,300 | -5.51% | |
| 2026-07-06 | Sale | Barchas Isaac | director | 83,094 0.0877% | $24.11 | $2M | -3.43% | |
| 2026-07-02 | Sale | Barchas Isaac | director | 100,000 0.11% | $22.59 | $2.26M | -2.18% | |
| 2026-07-02 | Sale | Lechleider Robert | Chief Medical Officer | 55,000 0.0551% | $22.62 | $1.24M | -2.18% | |
| 2026-06-30 | Sale | Barchas Isaac | director | 101,050 0.1054% | $21.12 | $2.13M | +8.99% | |
| 2026-06-25 | Sale | Lechleider Robert | Chief Medical Officer | 55,000 0.0589% | $19.85 | $1.09M | +18.61% | |
| 2026-06-15 | Sale | Rosett Max | Chief Financial Officer | 60,000 0.0633% | $18.23 | $1.09M | +26.12% | |
| 2026-06-05 | Sale | BIENAIME JEAN JACQUES | director | 10,500 0.0115% | $19.41 | $203,820 | +21.56% | |
| 2026-06-05 | BIENAIME JEAN JACQUES | director | 10,500 0.0115% | $19.45 | $204,260 | +21.56% | ||
| 2026-05-15 | BIENAIME JEAN JACQUES | director | 5,000 0.0052% | $20.70 | $103,500 | +6.23% | ||
| 2026-04-02 | Sale | Rosett Max | Chief Financial Officer | 65,000 0.0722% | $21.92 | $1.42M | +3.30% | |
| 2026-04-02 | Sale | Higgins Jack | Chief Scientific Officer | 9,438 0.0104% | $21.64 | $204,238 | +3.30% |
| SIEGALL CLAY B | President and CEO | 690704 0.5853% | $14.03M | 11 | 0 | +15.02% |
| WAGENHEIM PHILIP | director | 341147 0.2891% | $6.93M | 1 | 2 | <0.0001% |
| BIENAIME JEAN JACQUES | director | 43415 0.0368% | $881,758.65 | 9 | 1 | +32.71% |
| Tsai Philip | Chief Technical Officer | 43300 0.0367% | $879,423.00 | 3 | 0 | +21.26% |
| Lechleider Robert | Chief Medical Officer | 15805 0.0134% | $320,999.55 | 1 | 2 | +5.1% |
| RAPP MICHAEL | director | 208742 0.1769% | $4.24M | 7 | 0 | <0.0001% |
| LAMATTINA JOHN L | director | 51828 0.0439% | $1.05M | 1 | 0 | <0.0001% |
| Turner Bruce | Chief Strategy Officer | 42300 0.0358% | $859,113.00 | 1 | 0 | +74.21% |
| Lefenfeld Michael | director | 26872 0.0228% | $545,770.32 | 3 | 0 | <0.0001% |
| Sarma Purnanand D | President and CEO | 10500 0.0089% | $213,255.00 | 1 | 0 | <0.0001% |
$52,263,649 | 70 | 1.18% | $2.49B | |
$586,486,795 | 47 | 4.28% | $2.38B | |
$154,047,855 | 36 | 79.21% | $2.21B | |
$28,907,358 | 35 | 41.41% | $2.28B | |
$1,603,489 | 30 | 98.90% | $2.33B |
| Increased Positions | 125 | +94.7% | 37M | +40.35% |
| Decreased Positions | 56 | -42.42% | 10M | -10.46% |
| New Positions | 50 | New | 7M | New |
| Sold Out Positions | 20 | Sold Out | 5M | Sold Out |
| Total Postitions | 201 | +52.27% | 118M | +29.89% |
| Fmr Llc | $271,841.00 | 11.87% | 13.06M | +7M | +111.7% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $175,266.00 | 7.65% | 8.42M | +142,906 | +1.73% | 2025-09-30 |
| Blackrock, Inc. | $121,229.00 | 5.29% | 5.82M | +52,044 | +0.9% | 2025-09-30 |
| Redmile Group, Llc | $104,587.00 | 4.57% | 5.02M | +151,160 | +3.1% | 2025-09-30 |
| Vanguard Group Inc | $101,885.00 | 4.45% | 4.89M | +368,674 | +8.15% | 2025-09-30 |
| Point72 Asset Management, L.P. | $100,446.00 | 4.39% | 4.82M | +138,701 | +2.96% | 2025-09-30 |
| Enavate Sciences Gp, Llc | $99,282.00 | 4.34% | 4.77M | 0 | 0% | 2025-09-30 |
| Ecor1 Capital, Llc | $84,933.00 | 3.71% | 4.08M | 0 | 0% | 2025-09-30 |
| Price T Rowe Associates Inc /Md/ | $77,924.00 | 3.4% | 3.74M | +760,690 | +25.51% | 2025-09-30 |
| Opaleye Management Inc. | $66,312.00 | 2.9% | 3.19M | -344,581 | -9.76% | 2025-09-30 |